Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
